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Abstract
Background: Asthma is a common complex disease responsible for considerable morbidity and mortality,
particularly in urban minority populations. The Mechanistic Indicators of Childhood Asthma study was designed to
pilot an integrative approach in children’s health research. The study incorporates exposure metrics, internal dose
measures, and clinical indicators to decipher the biological complexity inherent in diseases such as asthma and
cardiovascular disease with etiology related to gene-environment interactions.
Methods/Design: 205 non-asthmatic and asthmatic children, (9-12 years of age) from Detroit, Michigan were
recruited. The study includes environmental measures (indoor and outdoor air, vacuum dust), biomarkers of
exposure (cotinine, metals, total and allergen specific Immunoglobulin E, polycyclic aromatic hydrocarbons, volatile
organic carbon metabolites) and clinical indicators of health outcome (immunological, cardiovascular and
respiratory). In addition, blood gene expression and candidate SNP analyses were conducted.
Discussion: Based on an integrative design, the MICA study provides an opportunity to evaluate complex
relationships between environmental factors, physiological biomarkers, genetic susceptibility and health outcomes.
Project approval: IRB Number 05-EPA-2637: The human subjects’ research protocol was reviewed by the
Institutional Review Board (IRB) of the University of North Carolina; the IRB of Westat, Inc., the IRB of the Henry
Ford Health System; and EPA’s Human Subjects’ Research Review Official.
Background
Asthma is a chronic disease of the airways involving air-
way inflammation, variable obstruction, hyper respon-
siveness, and respiratory symptoms. Asthma is a
significant problem worldwide that causes substantial
social impacts and costs to public and private health
systems [1]. Asthma is poorly understood in part
because of the myriad of complex genetic and environ-
mental components which influence both the develop-
ment and exacerbation of asthma.
Understanding the complex relationships between
environmental exposures and health outcomes such as
asthma requires consideration of a wide range of fac-
tors–both extrinsic (e.g., ambient air quality) and intrin-
sic (e.g., genotypic) that must be integrated to assess
cumulative risk and to support epidemiological studies
investigating gene-environment interactions. As under-
standing of how to assess and mitigate health risks
resulting from exposures to individual environmental
pollutants improves, environmental health scientists are
turning their attention toward characterizing relation-
ships between multiple environmental factors and com-
plex diseases. Although the association of genetic and
environmental factors in the development of disease has
long been recognized, promising tools for characterizing
global human genetic variation have only recently been
developed [2]. The study of the role of genetic variation
in human response to environmental exposures,
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“ecogenetics” [3], focuses on identifying markers of sus-
ceptibility and characterizing the modification of risk in
susceptible individuals. Recent technological advances
have led to the development of toxicogenomics which
examines the effects that chemicals have on living
organisms and/or the environment using genomic, pro-
teomic, and metabonomic methods [4]. These emerging
tools in molecular biology provide the potential for
development of cellular and molecular indicators of
exposure and health status that can be used to assess
the vulnerability of humans to environmental stressors.
In the Mechanistic Indicators of Childhood Asthma
study (MICA), biomonitoring and other health data are
used to characterize potential exposures and asthma-
related health outcomes. By considering an array of
metrics across the exposure-outcome continuum, this
framework begins to address the multi-factorial nature
of environmental disease and cumulative risk. Because it
is unlikely that a single “ideal” biomarker (a single mea-
sure with all the important characteristics for relating
health outcomes with a particular exposure) will be
identified, an array of biomarkers is measured to evalu-
ate the relationships.
An overarching hypothesis of MICA is that genomic
data viewed together with a spectrum of exposure,
effects, clinical and susceptibility markers: a) increases
the sensitivity needed to define exposure-response-
effects relationships, and b) provides mechanistic insight
useful from a clinical and environmental health context.
Specifically this rich data set will also be used to:
• Segregate asthma phenotypes and develop hypoth-
eses related to underlying biological mechanisms
through the application of multidimensional statistical
and knowledge-based approaches
• Identify panels of biomarkers from the array of
MICA exposure to health outcome covariates for future
application in large population studies by evaluating
reliability, predictive value, sensitivity, specificity, afford-
ability, and applicability.
• Identify impact of exposures on key pathways identi-
fied from the gene expression data.
• Evaluate genetic variants previously associated with
asthma outcomes in the MICA study population.
• Estimate individual and combined effects of environ-
mental exposures and genetic susceptibility in determin-
ing the likelihood of childhood asthma related
outcomes.
Methods/Design
The study design and protocols were approved by the
Institutional Review Boards at Henry Ford Health Sys-
tem (Detroit, MI), Westat Inc. (Rockville, MD), and the
University of North Carolina at Chapel Hill (Chapel
Hill, NC - US EPA’s IRB of record). Written consent
was obtained from guardians, and written assent was
obtained from each child, with an oral review of both
consent and assent prior to study enrollment. The
(MICA) study was conducted by the United States
Environmental Protection Agency between November
2006 and January 2007 in Detroit, Michigan. MICA is a
cross-sectional study based on a stratified sample of
children using two strata: children with asthma and chil-
dren without asthma, selected in an approximately 1:1
ratio. A total of 205 children age 9-13 years old partici-
pated in the clinical study.
The integrated study design and framework for MICA
is shown in Figure 1. The MICA design focuses on
environmental exposures, susceptibility, asthma and
other health measures, including risk factors associated
with obesity and cardiovascular disease. Information on
a wide range of risk factors relevant to asthma and
asthma exacerbations were characterized through collec-
tion of exposure (indoor and outdoor air pollution
monitors and home vacuum dust) lung function tests
and biological and clinical indicators measured in blood,
urine, and finger nails as shown in additional file 1,
Table 1.
Subject selection and recruitment
MICA is a nested study within the EPA’s Detroit Chil-
dren’s Health Study (DCHS) that identified 1,157 chil-
dren who completed health questionnaires as well as
clinical examinations of lung function and exhaled
breath [5]. From among these participants, a total of
205 non-asthmatic and asthmatic children aged 9-13
years were recruited into the MICA study at the Henry
Ford Health System (HFHS) clinic in Detroit, Michigan
over a 10-week time period (October 25, 2006 - January
6, 2007). Recruitment contact was made by mail and tel-
ephone by Henry Ford Health System (HFHS) and
involved repeated contacts in order to schedule the clin-
ical visit. HFHS identified asthmatic (100) and non-asth-
matic (100) children.
Inclusion Criteria
Children aged 9 to 12 years residing in the communities
of Detroit, Dearborn, Highland Park, or Hamtramck and
who are served by the Henry Ford Health System were
eligible for selection into the MICA study. Subjects were
recruited without regard to sex or ethnicity. A child was
considered asthmatic if the clinical record showed one
or more asthma-related emergency department visits,
two or more asthma-related outpatient visits, or two or
more asthma-related medications. From the parental
questionnaire, a child was considered asthmatic with a
parental report of a physician’s diagnosis of asthma.
Exclusion Criteria
Any child with a history of respiratory illness in the last
two weeks, or who had ever smoked five or more
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cigarettes, or who had been a carrier of a communicable
disease was excluded from the pulmonary function
examination. No child was excluded from participating
in the pulmonary examinations due to any chronic,
non-infectious respiratory problems or environmental
exposures. However, to control for potential confound-
ing by rare conditions with strong pulmonary effects,
the analysis of the environmental associations excluded
children with a history of cystic fibrosis, chest operation,
heart conditions, or who received oxygen for more than
two weeks after birth or at home. Children with any of
these conditions, with acute respiratory illnesses, or
active smokers were excluded from the pulmonary
exams.
Measurement Methods
Questionnaire A detailed questionnaire regarding the
child’s medical history and family history as well as the
child’s home environment was obtained. In addition, a
short questionnaire was obtained on the day of the
clinic visit to assess the child’s recent medical history
including smoking history, time-activity patterns and
summary of the child’s daily diet.
Participant-Based Residential Environmental Sam-
pling All MICA study participants were asked to bring
in a used vacuum cleaner bag to serve as a sample of
dust from the home environment. In addition, the par-
ents of a subset of asthmatic and non-asthmatic children
(n = 100) also completed a participant-based collection
of indoor and outdoor air samples from the children’s
homes that focused on passively measured nitrogen
dioxide (NO2), polycyclic aromatic hydrocarbons (PAH)
and volatile organic compounds (VOC) as shown in
Figure 1 and additional file 1, Table 1.
Lung Function, Expired Nitric Oxide, Serum Based
Allergen Sensitivity Tests Spirometry was performed
with an automated spirometer consistent with American
Thoracic Standards. Lung function measurements were
repeated 3-8 times and exhaled nitric oxides test were
repeated 3-5 times for accuracy. Breathing tests (forced
expiratory volumes and expired nitric oxide) were
Figure 1 The overall study design includes exposure, biomarkers of exposure, clinical indicators, genomic data (blood gene
expression and SNP) and health status indicators.
Gallagher et al. BMC Public Health 2011, 11:344
http://www.biomedcentral.com/1471-2458/11/344
Page 3 of 6
recorded on chart data sheets. Total IgE and allergen
specific IgE levels for a multi-allergen screen were quan-
tified for each subject’s blood. The multi-allergen screen
detects the presence (positive/negative) using a panel of
at least 15 common aeroallergens and 5 common food
allergens.
Height, Weight, Blood Pressure and Blood Oxygen
Height and weight measurements were obtained. A
trained technician measured the child’s blood pressure
with oscillometric digital blood pressure monitor and
repeated the measure three times. Blood oxygen was
measured with a portable pulse oximeter.
Blood Sample Collection Blood from non-fasting chil-
dren (approximately 50 mls) was drawn into10 separate
Vacutainer™ tubes in the following order: 5 mls into 2-
2.5 ml/tube (PAXgene Qiagen, Valencia, CA, USA); 15
mls into 3-6 ml/tube serum separator tubes; 2 mls into
2-3 ml/tube minicollector EDTA-containing tubes; and
2, 9, and 4 mls into 3 sodium citrate tubes. HFHS con-
ducted analyses of CBC, Pb and Hg using standard
methods as mandated by CLIA (Clinical Laboratory
Improvement Amendments). All other measurements in
blood are listed in additional file 1, Table 1.
Urine and Fingernail Collection Urine was collected
from each child in a container that was fitted to the top
of the toilet lid. Each child was also asked to clip his/
her fingernails and/or toenails which were placed in two
separate plastic Ziploc bags. Measurements in urine and
nails are listed in additional file1, Table 1.
Molecular Markers
Single Nucleotide Polymorphisms (SNPs) SNP geno-
types were selected as candidate SNPs (HLA-DRB1,
HLA-DQB1, FCER1B, ADAM33, CD14, IL4, IL13,
GSTM1, GSTP1, GSTT1, and TNF). The rationale for
selection of the 11 specific genes and relevant SNPs is
based on relevant studies in which associations between
asthma and specific genotypes were evaluated. The
SNPs were selected by querying public databases for
polymorphisms showing variation in African American
(AA) samples, since that race was overrepresented. For
genes with no AA variable SNPs in the databases, we
selected based on studies reported in the literature. To
rank the available SNPs within each gene, we used a
simple “weight of evidence” summation.
Whole Blood Gene expression Peripheral blood samples
collected in PAXgene blood RNA tubes (Qiagen, Valen-
cia, CA, USA), were inverted several times to mix, held
at room temperature for 24 hours to lyse red blood
cells, and then stored at -80°C. The PAXgene blood
tubes contain reagents to stabilize RNA in blood. Frozen
blood samples were transported to the US EPA on dry
ice and stored at -80°C until RNA was isolated. Total
RNA was isolated using DNase treatment. RNA quality
was checked using an Agilent Bioanalyzer. 2.5-5.0 mg of
each sample was sent to Expression Analysis (Durham,
NC) for cDNA target generation and hybridization to
Affymetrix Human U133 Plus 2.0 whole genome arrays.
Database/Data Analysis
Database The MICA database is derived from the
MICA data collection and samples. The database is
maintained and updated in Access (Microsoft) and SAS
(version 9.1, Cary, NC) databases and contains anon-
ymized MICA Study participant data and results of sam-
ple analyses. All personal information provided by the
subject to the investigators and all information that is
collected about the subject by the investigators’ subject
identifiers have been stripped from all data records.
Analytic data is identified through subject ID numbers.
The Database lists the names of the MICA data tables
and provides a brief description of the contents of those
tables. Additional file 1, Table 1 lists the named vari-
ables for the MICA data tables.
Sample Size/Power calculations MICA allows for the
comparison of multiple markers of exposure, effects, and
susceptibility in asthmatic and non asthmatic children.
Power calculations were performed prior to data collec-
tion to estimate the sample size needed to address the
major aim of the gene expression study: identification of
biomarkers/factors associated with differential asthma
susceptibility. The calculations were performed using the
Two Sample Means option in the SAS POWER proce-
dure. Estimates of the sample size needed to detect a 2-
fold difference in mean group (i.e. asthmatics versus non-
asthmatics) expression with 80% power and a stringent
false-positive (alpha) rate of 1/2500 were performed. All
calculations assumed the same sample proportions and
measurement variance (expressed as standard deviations)
in each group. The standard deviations for the log2 trans-
formed measurements were varied from 0.25 to 1.0,
which is in-line with observed standard deviation:mean
ratios in other studies. Even with the stringent false-posi-
tive collar of 0.0004, under the most pessimistic variance
scenario, the estimated sample size needed for each
group was 42. The final study used a sample size of
roughly twice this estimate (100 per group) in order to
account for violation of the assumptions underlying our
power calculations and the possibility of subgroups within
the clinical asthma classes.
Data Analysis Multivariate linear regression models will
be used to test the association of exposures with internal
measures of exposure, effect and susceptibility. Adjust-
ments will be made for confounding and effect modify-
ing exposures. Curves will be generated for non-
asthmatics and asthmatics and tested for statistical dif-
ferences between them. Separate curves will be drawn
based on differences in individual polymorphisms, atopic
status using individual and combined indexes for expo-
sure and effects markers.
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Statistical Analysis of Gene expression and SNP data
Exposure biomonitoring and clinical data from asth-
matic and non-asthmatic children will be viewed in the
context of markers of effect and susceptibility. The com-
putational analysis needed to ultimately integrate the
data across the sources to outcome paradigm is enor-
mous, requiring data access and management, data
mining, data interchange and data reduction. Since
neither covariate data nor gene expression data alone
unambiguously separates asthmatics from non-asth-
matics, correlation between covariates and gene expres-
sion will be considered in order to provide context for
each type of data. It is anticipated that incorporation of
the covariate information will enhance the functional
significance of gene clusters, and knowledge of covari-
ate-association(s) should provide a biological context
with which to interpret gene expression results.
Data analysis method(s) applied will include techni-
ques from various fields • Traditional statistics: linear
regression, logistic regression, ANOVA, linear discrimi-
nant analysis.
• Machine learning: recursive partitioning trees, boot-
strap aggregation (bagging) techniques, evolutionary
computation-optimized classifiers, multifactor dimen-
sionality reduction, random forests.
• Bioinformatics: protein interaction databases, knowl-
edge (literature) mining tools, biological pathway data-
base and inference software.
• Graphical approaches: cluster diagrams, expression
“heat” maps, dendrograms, overlaid scatter plots (both
exploratory and summary), distributional “violin” plots,
regression plots.
Discussion
Past approaches for designing studies and evaluating
collected data have tended to focus on a limited number
of environmental factors and/or measures of outcome
and are rarely conducted with children. The (MICA)
study design represents an integrative approach in chil-
dren’s health research that incorporates exposure
metrics, internal dose measures, clinical indicators and
blood gene expression measures to decipher the biologi-
cal complexity inherent in diseases with etiology related
to complex gene-environment interactions. The coordi-
nated collection of these complimentary data provides a
platform for applying systems approaches to evaluate
complex relationships between environmental factors,
physiological biomarkers, and health outcomes. The
study can be used to inform the design of future envir-
onmental health studies and facilitate the interpretation
of study results for public health decision making.
The analysis of transcriptional responses in blood
coupled with biomonitoring data should provide
mechanistic insight into the biological pathways that are
perturbed in response to single chemicals or complex
mixture exposures. Bioindicators for these biological
pathways can then be incorporated into future biomoni-
toring studies to link the biomarkers of exposure to a
relevant apical endpoint.
While MICA is an asthma study, this rich data set can
be explored for relationships between early indicators of
cardiovascular disease, obesity, and asthma and to
demonstrate the complex nature of childhood health
and environmental disease. For example, a myriad of
disease risk factors/modifiers often compromise the eva-
luation of a single disease. The risk of developing heart
disease increases to over six fold [6] with the combina-
tion of the following three risk factors: high blood pres-
sure, high cholesterol and diabetes. Obesity is associated
with numerous co-morbidities such as cardiovascular
diseases, type 2 diabetes, hypertension, and certain can-
cers [7]. Metabolic syndrome as described by Wilson et
al. [8] occurs as a constellation of obesity, hypertension,
dyslipidemia, and insulin resistance leading to diabetes.
MICA blood gene expression data, viewed in the context
of phenotypic data relevant to asthma, cardiovascular
risk, and obesity, may provide insight into exposure
assessment, pathophysiology of asthma and early indica-
tions of cardiovascular disease and metabolic syndrome.
MICA provides an opportunity to pilot the application
of a more holistic analytical approach to improve the
interpretation of biomarker data to advance both
mechanistic based toxicology and risk assessments of
chemical (single, multiple, and complex mixtures) expo-
sures. Whether and to what extent these exposures
impact such a distinctive and diverse set of health out-
comes such as asthma, cardiovascular disease and meta-
bolic syndrome, are central to the MICA study
objectives. Ultimately, the goal is to identify a specific
and sensitive panel of molecular and traditional environ-
mental and clinical markers from the myriad of indica-
tors included in the MICA study design, and in doing
so, gain mechanistic understanding of potential gene
environment interactions that will inform design of
future clinical and epidemiological studies in humans.
Additional material
Additional file 1: Table 1 The exposure, biomarkers, clinical
indicators, and genetic variables measured in MICA.
Abbreviations
AA: African American; BP: Blood pressure; BMI: Body mass index; BUN: Blood
urea nitrogen; CCE: Cladosporium cladosporiodes; CLIA: Clinical lab
improvement methods; DCHS: Detroit children’s health study; feno: forced
expired nitric oxide; HDM: House dust mite extract; HFHS: Henry Ford Health
System; IgE: Immunoglobulin E; IRB: Institutional Review Board; MCV: Mean
cell volume; MCH: Mean cell hemoglobin; MICA: Mechanistic Indicators of
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Childhood Asthma Study; MACA: Metarhizium anisopliae; LDL, HDL VLDL:
Low, high and very low density lipoprotein; MM1 and MM2: Mold Mix 1 and
2; NO2: Nitrogen dioxide; OHNAP1and 2-hydroxy-naphthalene; OHFLU: 2-
hydroxy fluorine; OHPHE: 1-,2-&3-,4-and 9-hydroxy phenanthrene; OHPYR:1-
hydroxy-pyrene; NO2: Nitrogen dioxide; PAH: Polycyclic aromatic
hydrocarbons; PCE: Penicillium hhrysogenum; RDW: red blood cell
distribution width; VOC: Volatile organic carbons; SCE: Stachybotrys
chartarum; ALT (SGPT): Serum Glutamic pyruvic transaminase; SNPs: Single-
nucleotide polymorphisms.
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